Veracyte, Inc.

This week: @PhilFebboMD_CMO, Chief Scientific and Medical Officer at Veracyte, will be speaking at #PMWC26 on the future of whole-genome MRD and precision diagnostics. 📅 March 5, 2:30 PM PST Talk: "Improving Care with Every Test: Powering a Continuous Learning Cycle in Molecular Diagnostics" 💬 March 6, 1:30 PM PST Panel: "Diagnostics, Prognostics, and Patient Stratification" Learn more - pmwcintl.com/speaker/phil-f… #TrueMRD #ctDNA #PrecisionMedicine #OncologyResearch #GenomicTesting #CancerDiagnostics #WholeGenomeSequencing

We are excited to announce that more than 15 abstracts featuring our urology portfolio will be presented this week at the 2026 ASCO Genitourinary Cancers Symposium (#ASCOGU). The abstracts span studies across prostate and bladder cancers, featuring: 🔹 Real-world data for Decipher Prostate 🔹 New insights from phase II clinical trials, including one utilizing our upcoming TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test “The breadth of data at ASCO GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. Read press release - investor.veracyte.com/news-releases/… #Decipher #TrueMRD #MRD #ASCOGU2026 #CancerDiagnostics #UrologicCancer #PrecisionMedicine

Veracyte will report financial results for Q4 and full year 2025 on Wednesday, Feb. 25, at 4:30 PM ET. Join our conference call and webcast for a full financial update and general business overview. 🔗 Access the webcast here: lnkd.in/gTMvRAap #Veracyte #Q4Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT

On Thursday at PM ET, join our live webcast from the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. 🔗 The live audio webcast will be accessible here: investor.veracyte.com/events-present… 📄 Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results: investor.veracyte.com/news-releases/… #FinancialResults $VCYT #CancerDiagnostics #PrecisionMedicine #JPM2026 Disclaimer: veracyte.com/cautionary-not…

Today, we announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter of 2025, compared to the same period in 2024, we expect to report: 🔹Total revenue of between $138 million and $140 million, an increase of between 16% and 18% 🔹Testing revenue of between $134 million and $136 million, an increase of between 19% and 21% 🔹Testing volume of approximately 45,500, an increase of 16% Press Release: investor.veracyte.com/news-releases/… Disclaimer: veracyte.com/cautionary-not… #Veracyte #FinancialResults #Biotech $VCYT #CancerDiagnostics #PrecisionMedicine #JPM2026

#TeamVeracyte is excited to be at #SABCS25 and connect with oncologists, researchers, and colleagues advancing breast cancer care. 🤝 Stop by Booth #1432 to meet our team and discover how the #Prosigna Breast Cancer Assay is helping guide treatment decisions for women with early-stage HR+ breast cancer. We look forward to great conversations and exploring new research. When we get together, breast cancer diagnostics get ahead! #Veracyte #BreastCancer #ProsignaBreastCancerAssay #PrecisionMedicine #MedicalOncology #WomensHealth #BreastCancerResearch #GenomicTesting #PersonalizedMedicine #Oncology #Biotech #CancerCare

As we gather in San Antonio this week for #SABCS25, we're reminded of the importance of precision medicine in breast cancer care. We look forward to connecting with oncologists, researchers, and colleagues, because when we get together, breast cancer diagnostics get ahead. | The Challenge | Globally, breast cancer remains the most common cancer among women, with over 2.3 million new cases reported in 2022. In the US alone, an estimated 319,750 people will be diagnosed with invasive breast cancer in 2025, with about 70% - more than 225,000 - expected to have hormone receptor-positive breast cancer. | Our Approach | At Veracyte, we're committed to providing clinicians with comprehensive genomic insights to confidently guide treatment decisions for patients. Our #Prosigna Breast Cancer Assay helps inform personalized treatment planning for patients with early-stage breast cancer. 🔗 Read our latest article to learn how genomic testing is unlocking the power of truly personalized breast cancer care: linkedin.com/pulse/breast-c… | Connect with us at SABCS 2025 | 🤝 Visit Booth #1432 to connect with #TeamVeracyte and discuss how intrinsic molecular subtyping is transforming treatment decisions for women with HR+ breast cancer. #Veracyte #BreastCancer #ProsignaBreastCancerAssay #PrecisionMedicine #GenomicTesting #PersonalizedMedicine #MedicalOncology #WomensHealth #BreastCancerResearch #ClinicalResearch #Oncology #Biotech #CancerCare

LIVE WEBINAR - Dec 5: Phillip G. Febbo, MD, as he introduces our Veracyte #TrueMRD platform and its utility in tumor-informed circulating tumor DNA (ctDNA) analysis for monitoring minimal residual disease (#MRD), treatment response, and clonal evolution. Gain insights into how WGS-based ctDNA profiling enables: 🔹 Earlier detection of disease recurrence 🔹 Sensitive MRD monitoring 🔹 Deeper whole-genome insights 🔹 More personalized drug development and patient management 📅 Dec 5 | 10am PT / 1pm ET 🔗 Register now: event.on24.com/wcc/r/5116356/… #ctDNA #LiquidBiopsy #PrecisionMedicine #ClinicalTrials

A new UK trial called #INTENSIFY is using the Veracyte #DecipherProstate test to help personalize treatment for advanced prostate cancer patients. The trial will look at whether selecting patients who may require more intensive treatment can improve outcomes for advanced prostate cancer. The aim is to improve survival by delaying the progression of metastatic cancer. 🔹 Read article: southampton.ac.uk/ctu/news/2025/… 🔹 Explore Decipher Prostate: decipherbio.com/decipher-prost… #DecipherUrologicCancers #ProstateCancer #MetastaticProstateCancer #PrecisionMedicine #UrologicOncology #ClinicalTrial #UKResearch #GenomicTesting #PersonalizedMedicine #CancerResearch #Biotech #Urology #AdvancedProstateCancer

The Pathologist features a Q&A with Phil Febbo, MD, Chief Scientific Officer and Chief Medical Officer at Veracyte, exploring what the #STAMPEDE trial reveals about utilizing gene expression testing to predict chemotherapy benefits and help improve prostate cancer outcomes. This comprehensive conversation examines the research that's shaping the future of precision medicine in prostate cancer care. 📄 Read the full Q&A: thepathologist.com/issues/2025/ar… #DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #GenomicTesting #ClinicalResearch #Pathology #CancerDiagnostics #PersonalizedMedicine #Biotech

#UroToday has a video presentation featuring Daniel Spratt, M.D., discussing the groundbreaking NRG GU006/BALANCE trial results, which demonstrates that the Decipher GRID-enabled biomarker, PAM50 (adapted for prostate cancer), predicts hormone therapy benefit in men with recurrent prostate cancer. Watch: urotoday.com/video-lectures… Press release on new data: investor.veracyte.com/news-releases/… #ProstateCancer #PrecisionMedicine #BALANCETrial #GenomicTesting Disclaimer: veracyte.com/cautionary-not…

Incredible energy at #ESMO2025 in Berlin this past weekend! Thank you to the clinicians, researchers & collaborators who stopped by to connect with #TeamVeracyte. We’re proud to serve clinicians who serve patients facing cancer. Our molecular tests provide insights that help guide pivotal decisions—those that can significantly change the course of each patient's care and improve outcomes. #PrecisionMedicine #OncologyInnovation #CancerDiagnostics

High-risk localized prostate cancer represents a heterogeneous group at the molecular level. In a recent analysis of samples from the phase 3 NRG/RTOG 0521 trial, #DecipherProstate delivered independent prognostic insights beyond traditional clinical factors, helping assess metastasis-free survival (MFS) and distant metastasis risk in patients with high-risk, nonmetastatic prostate cancer. Importantly, a subset of patients with very high Decipher scores (>0.85) had a distinctly worse prognosis: more than a 2-fold higher risk of MFS events compared with low/intermediate scores, and the highest 10-year cumulative incidence of distant metastasis. These findings underscore Decipher’s value in identifying high-risk patients who may benefit from intensified therapy and in guiding personalized treatment decisions. | Resources | 🔹Read the abstract: lnkd.in/e8XwwUUa 🔹Explore Decipher Prostate: lnkd.in/gf--GyzM #DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #UrologicOncology #GenomicTesting #PersonalizedMedicine #ClinicalResearch #Biotech #Urology #CancerDiagnostics #NRGOncology

New data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the #PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from hormone therapy with apalutamide in addition to salvage radiation therapy. The prostate PAM50 biomarker is currently available for Research Use Only on the Decipher GRID (Genomic Resource for Intelligent Discovery) research tool. New findings were shared by Daniel Spratt, M.D. at #ASTRO25 in San Francisco. Press release: investor.veracyte.com/news-releases/… Disclaimer: veracyte.com/cautionary-not… #ProstateCancer #DecipherUrologicCancers #PrecisionMedicine #UrologicOncology

Incredible week at #ATAThyroid2025! Congratulations to #GenevieveSpagnuolo, MD, MBS on winning the 2025 Outstanding Trainee Poster Award from the #AmericanThyroidAssociation. Her research: "Preoperative Thyroid Nodule mRNA Expression Signatures to Predict Postoperative Thyroid Histopathology" Thank you #TeamVeracyte and our collaborators. We're grateful to be part of the ATA community and proud to continue advancing thyroid nodule research. Learn more: afirma.com #ThyroidNoduleResearch #AfirmaGSC #PrecisionMedicine

#TeamVeracyte is thrilled to be at #ATATHYROID2025! 📊 New data: At least 12 Afirma-related abstracts will be presented this week in Scottsdale. If you missed the presentations, click on the links below to learn more.  Press release: investor.veracyte.com/news-releases/… Complete list of Afirma-related abstracts: veracyte.com/event/annual-m… Visit us at Booth #301 today! #AfirmaGRID #ThyroidCancer #ThyroidResearch #Endocrinology #ENT #ThyroidNodules #PrecisionMedicine #MolecularDiagnostics #ClinicalResearch #Biotech #CancerDiagnostics

We're thrilled to announce at least 12 Afirma-related abstracts will be presented this week at #ATATHYROID2025 in Scottsdale. The large number of abstracts stems from our extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles—which is the largest dataset of its kind in thyroid cancer research—and our Afirma GRID research tool. Press release: investor.veracyte.com/news-releases/… Abstract list: veracyte.com/event/annual-m… #ThyroidCancer #AfirmaGRID #Endocrinology #ThyroidResearch #Biotech Disclaimer: veracyte.com/cautionary-not…

New data published in Cell show that Decipher® Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with docetaxel chemotherapy, as well as those who are not and may therefore avoid unnecessary toxicity. These findings, from the randomized, prospective, Phase 3 STAMPEDE trial, are the first to be published showing that a gene expression test can help clinicians better personalize chemotherapy decisions for patients with metastatic prostate cancer. Read more: investor.veracyte.com/news-releases/… #DecipherUrologicCancers #ProstateCancer #STAMPEDE #CellJournal #PrecisionMedicine #biotech Disclaimer: veracyte.com/cautionary-not…

This week, we have met our enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of our Percepta Nasal Swab test. NIGHTINGALE is a prospective, multicenter, randomized trial that Veracyte is sponsoring to evaluate Percepta Nasal Swab test's ability to improve clinical decision-making for patients with lung nodules—helping to reduce unnecessary invasive procedures for patients with benign nodules while ensuring faster treatment for those with cancerous nodules. Read more: investor.veracyte.com/news-releases/… #Veracyte #NIGHTINGALE #LungCancer #ClinicalTrial #Biotech #TrialMilestone #PerceptaNasalSwab Disclaimer: veracyte.com/cautionary-not…